Insmed reported $214.26M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Cytokinetics USD 122.26M 145K Dec/2025
DBV Technologies USD 136.82M 51.98K Sep/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 214.26M 1.67M Dec/2025
Novartis USD 1.91B 10.64M Dec/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025